AstraZeneca PLC (NASDAQ: AZN) disclosed today that its Imfinzi has received approval for a new dosing option in the US for the treatment of small-cell lung cancer. FDA has granted this option after reviewing the various Imfinzi trials including the CASPIAN Phase III trial
